Vila et al., “Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine and Hydroxycarbamide,” Lancet, 350, 635-636 (Aug. 30, 1997).* |
Mellors et al., “Mutations in HIV-1 Reverse Transcriptase and Protease Associated with Drug Resistance,” International Antiviral News, 3(1), 8-13 (1995).* |
Richard et al. (I), “Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants Resistant to the (+) and (31 ) Enantiomers of 2′-Deoxy-3′-Thia-5-Fluorocytidine,” Antimicrobial Agents and Chemotherapy, 44(5), 1127-1131 (May, 2000).* |
Richard et al. (II), “Selection and Characterization of HIV-1 Variants Resistant to the (+) and (−) Enantiomers of 2′-Deoxy-3′-Oxa-4′-Thia-5-Fluorocytidine,”Antiviral Therapy, 4(3), 171-177 (1999).* |
Buckheit et al., “Structure -Activity and Cross-Resistance Evaluation of a Series of Human Immunodeficiency Virus Type 1-Specific Compounds Related to Oxathiin Carboxanilide,” Antimicrobial Agents and Chemotherapy, 39(12), 2718-2727(Dec., 1995).* |
Hammond et al., “Mutations in Retroviral Genes Associated with Drug Resistance,” a review article in Human Retrovirus and AIDS: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences, Los Alamos National Laboratories, Los Alamos, NM, 1999, pp. 542-591.* |
Hirsch et al., “Anti-retroviral Drug Resistance Testing in Adults with HIV Infection,” JAMA, (Jun. 24, 1998), vol. 279(24), p1984-1991. |
Merrill et al. “Enzymes of ceramide biosynthesis,” Methods Enzymol., (1992), vol. 209, pp. 427-437. |
Merrill, Jr., et al., “Lipids and Lipid-Like Compounds of Fusarium, ” Ch. 9, Lipids of Pathogenic Fungi, Prasad et al. (eds.), CRC Press, Inc., New York, NY, 1996, only pp. 199-217 supplied. |
Merrill, Jr. et al., “Toxicity of Fumonisin B.sub.1 for Renal Cell Carcinoma and Other Tumor Lines: A New Class of Possible Chemotherapeutic Agents,” Abstract No. 1367, Proceedings American Urological Association. 155(5), p. 653A (Supplement, May, 1996). |
Nilsson, A., “Metabolism of sphingomyelin in the intestinal tract of the rat,” Biochim. Biophy. Acta., (Dec. 1968), vol. 164(3), pp. 575-584. |
Schinazi et al., “Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1[-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.” Antimicrobial Agents Chemotherapy. (1992) 36(11): 2423-2431. |
Schinazi et al. “Characterization of human immunodeficiency virus resistant to oxathiolane-cytosine nucleosides.” Antimicrobial Agents Chemotherapy. (1993) 37(4): 875-881. |
Schinazi et al., “Mutations in retroviral genes associated with drug resistance,” International Antiviral News, International Medical Press 1997. (vol. 4, No. 6, pp. 95-107). |
Schmelz et al., “Uptake and metabolism of sphingolipids in isolated intestinal loops of mice,” Journal of Nutrition, May 1994, vol. 124, Issue 5, pp. 702-712. |
Stuyer L., et al. “Line proble assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.” Antimicrobial Agents & Chemotherapy (Feb. 1997) 41(2): 284-91. |
Bennun et al., Infect & Immun., 57:969-74, 1989. (Issue No. 3, 03-00-1989). |
Bell, R., et al. Cold Spr. Harbor Sym. Quant. Biol. 53:103, 1988. |
Buehrer and Bell, J. Biol. Chem. 267:3154-3159, 1992.(Iss. No. 5; Feb. 15, 1992). |
Buehrer and Bell, Adv. Lipid Res. 6:59-67, 1993. |
Colla, et al., Eur. J. Med. Chem.-Chim. Ther.295-301 (1985). (vol. 20, No. 4). |
Crossman and Hirschberg, J. Biol. Chem, 252:5815-5819, 1977. (Iss. #16: Aug. 25, 1977). |
Farkas-Himsley et al., Proc. Natl. Acad. Sci. (USA) 92:6996-7000, 1995.(#15; Jul. 18, 1995). |
Guatelli et al. Proc. Natl. Acad. Sci, (USA), 1874-1878, (Mar. 1990).(vol. 87, No. 5). |
Hakomori,, J. Biol. Chem. 265:18713-18716, 1990. (Iss. No. 31; Nov. 5, 1990). |
Hannun et al., J. Bio. Chem. 261:12604-12609, 1986 (Iss. No. 27; Sep. 25, 1986). |
Hannun, J. Biol. Chem. 269:3125 3128, 1994. (Iss. No. 15; Feb. 4, 1994). |
Hannun and Obeid, Trends Biochem, Sci. 20:73-77, 1995. (Feb. 1995). |
Jacewicz et al., J. Clin. Invest. 96:1328-1335, 1995. (Sep. 1995). |
Jefferson, A. and Schulman, H., J. Biol. Chem. 263:15241. 1988. (#30; Oct. 25, 1988). |
Karlsson, K. A., Chem. Phys. Lipids, 5:6-43, 1970. (Iss. No. 1; 10-00-1970). |
Kawai, G. et al., Stimulatory effect of certain plant sphingolipids on fruiting of Schizophyllum. |
Keusch et al., Infect & Immun. 63. 1138-1141; 1995. (Iss. No. 3; 03-00-1995). |
Kolesnick, Cell 77:325-328, 1994. (Iss. No. 3; Mar. 6, 1994). |
Larder et al., Science, 243:1731-1734 (1989). (Mar. 31, 1998). |
Larder et al., Science, 246, 1155-1158 (1989). (Dec. 1, 1989). |
Lin and Mancini, J. Med. Chem. 26, 544-548 (No. 4; Apr. 1983). |
Lin et al., J. Med. Chem. 26, 1691-1696 (1983) (Issue No. 12). |
Merrill et al., J. Biol. Chem. 261:3764-3769, 1986. (Iss. No. 8; Mar. 15, 1986). |
Merrill & Sweeley, “Sphingolipids: metabolism and cell signalling,” New Comprehensive Biochemistry. |
Minn, A. J., et al., Blood 86: 1903-1910, 1995. (Iss. No. 5; Sep. 1, 1995). |
Minn, A. J., et al., Nature, 385: 353-357, 1997. (Jan. 23, 1997). |
Morrison, Biochim. Biophys. Acta., 176:537-546, 1969. |
Muchmore, S. W., et al., Nature, 381: 335-341, 1996 (May 23, 1996). |
Patent Abstracts of Japan, vol. 095, No. 002, Mar. 31, 1995. |
Pittet, D., et al., J. Biol. Chem. 262:10072, 1987 (Iss. No. 21; Jul. 25, 1987). |
Robson et al , J. Lipid Res. 35:2060-2088, 1994.(Iss. No. 11; Nov., 1994). |
Rooke et al. Antimicrobal Agents Chem, 988-91 (May 1991). (vol. 35, No. 5). |
Schinazi R et al., Activity of 3′-azido-3′-deoxythymidine nucleotide dimers in primary lymhocytes. |
Thompson, et al., Biochem. Pharmacol. 56: 591-597, 1998.(Iss. No. 4; Aug. 15, 1998.). |
Wells, G. B. and Lester, R.L., J. Biol. Chem., 258:10200-10203, 1983(#17; Sep. 10, 1983). |
Wilson et al., J. Biol. Chem. 261:12616-12623, 1986. (Iss. No. 27; Sep. 25, 1986). |
Winicov, I. and Gershengorn, M., J. Biol. Chem. 263:12179, 1988. (#25; Sep. 5, 1988). |
Wu et al., J. Biol. Chem. 268:13830-13837, 1993.(Iss. No. 19; Jul. 5, 1993). |